Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.92%
#2 Palladium Network Palladium Network +8.47%
#3 Cryptopia Cryptopia +4.23%
#4 Victoria VR Victoria VR +4.09%
#5 Lisk Lisk +3.02%
#6 Test Test +2.89%
#7 GRVT Token GRVT Token +2.39%
#8 Biconomy Biconomy +2.25%
#9 COTI COTI +2.22%
#10 Bless Bless +2.18%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Adynxx, Inc. Adynxx, Inc.

Adynxx, Inc.

ADYX
Clasificación en acciones #42632
Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating... Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of transcription factor decoys, which includes brivoligide, currently progressing through Phase II clinical development for reducing post-surgical discomfort. Additionally, AYX2 is a pre-clinical candidate being explored for its potential in treating localized chronic pain. Established in 2007, the company's corporate headquarters are situated in San Francisco, California.
Precio por acción
$0.0001
Última sincronización: 2026-08-11
Capitalización bursátil
$581.00
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Adynxx, Inc. (ADYX)

Categoría

Healthcare
Ganancias de Adynxx, Inc. (ADYX)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Adynxx, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Adynxx, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR